Literature DB >> 2657043

Maintenance therapy of cyclical mastalgia using low-dose danazol.

B J Harrison, P R Maddox, R E Mansel.   

Abstract

In an open study, low-dose danazol (mean total dose 700 mg/month) was given during the luteal phase to 20 women with severe relapsing cyclical mastalgia. All subjects had previously obtained a useful clinical response on conventional dosage of danazol, but side effects occurred in 13 (65%). On the low-dose regimen, complete relief of symptoms was attained by 11 women (55%) and the remainder achieved a substantial clinical improvement; no side effects were reported. A low-dose regimen may be suitable for women with chronic relapsing cyclical mastalgia or those who develop side effects on conventional dosage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657043

Source DB:  PubMed          Journal:  J R Coll Surg Edinb        ISSN: 0035-8835


  6 in total

1.  Effectiveness of Centchroman on Regression of Fibroadenosis and Mastalgia.

Authors:  Udayakumar Rajswaroob; Rajendiran Kannan; Narayanasamy Subbaraju Kannan; T Tirouaroul
Journal:  J Clin Diagn Res       Date:  2016-10-01

2.  The long-term course of mastalgia.

Authors:  E L Davies; C A Gateley; M Miers; R E Mansel
Journal:  J R Soc Med       Date:  1998-09       Impact factor: 5.344

Review 3.  Management of breast pain and nodularity.

Authors:  P R Maddox; R E Mansel
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

Review 4.  Drug therapy of mastalgia. What are the options?

Authors:  P A Holland; C A Gateley
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

5.  Role of centchroman in regression of mastalgia and fibroadenoma.

Authors:  Anita Dhar; Anurag Srivastava
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

6.  Drug treatments for mastalgia: 17 years experience in the Cardiff Mastalgia Clinic.

Authors:  C A Gateley; M Miers; R E Mansel; L E Hughes
Journal:  J R Soc Med       Date:  1992-01       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.